Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease

Comment

Christoph Laske. N Engl J Med. 2014.

. 2014 Apr 10;370(15):1459.

doi: 10.1056/NEJMc1402193.

No abstract available

Comment in

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
Doody RS, Farlow M, Aisen PS; Alzheimer’s Disease Cooperative Study Data Analysis and Publication Committee. Doody RS, et al. N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193. N Engl J Med. 2014. PMID: 24716687 No abstract available.
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
Salloway S, Sperling R, Brashear HR. Salloway S, et al. N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193. N Engl J Med. 2014. PMID: 24724181 No abstract available.

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Doody RS, et al. N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889. N Engl J Med. 2014. PMID: 24450890 Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.